ClinicalTrials.gg
Sign In
Drug

CDK4 Inhibitor BGB-43395 clinical trials

Also written BGB-43395.

studies test it
4
open now
2
in phase 3
1
first study started
2024

How each study uses CDK4 Inhibitor BGB-43395 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the CDK4 Inhibitor BGB-43395 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

BGB-43395
4

Studies by the year they started

4 studies that test it; most in 2026 (2)

Studies that test CDK4 Inhibitor BGB-43395, by start year
YearStudies
20241
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 3
1

Who runs them

Industry 4 · Other 0

BeOne Medicines (3) · BeiGene (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test CDK4 Inhibitor BGB-43395.

Studies

Open first, then newest update. How each study uses CDK4 Inhibitor BGB-43395 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Given beside what is tested · 4 — CDK4 Inhibitor BGB-43395 is usual care or a partner of the new treatment